Proud to Partner With:
Guardant Health is a pioneer in non-invasive cancer diagnostics, addressing challenges across the cancer care continuum. The company has raised more than $200 million from leading venture capital firms and in 2014 launched Guardant360, the first comprehensive liquid biopsy for clinical use. Guardant Health is improving therapy selection for advanced cancer patients across the globe using its proprietary cell-free circulating tumor DNA NGS platform. Guardant Health is partnered with biopharmaceutical companies to prospectively screen patients for trial enrollment, develop companion diagnostics to support clinical adoption, and use retrospective analysis for early insights into patient response and tumor evolution, as well as accelerate the development of new therapies
Program & Panel Partner
We are committed to advancing patient care by offering a proven portfolio of comprehensive genomic profiling products that help physicians make more informed care decisions. Through constant innovation in molecular insights, we are dedicated to working with our partners to deliver breakthroughs that improve outcomes for more individuals living with cancer and bringing them to routine cancer care every day. That’s why we foster a collaborative culture that motivates us to do our best work and be a partner in every patient’s journey. Our approach offers not just test results, but the highest quality insights that can help doctors match patients to more treatment options and help accelerate the development of new therapies.
QIAGEN serves more than 500,000 customers around the globe, all seeking answers from the building blocks of life – DNA, RNA and proteins. We deliver Sample to Insight solutions for molecular testing, propelling our customers from start to finish to unlock new insights. This is how we make improvements in life possible.
Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic Sciences’ mission is to enable the rapid and noninvasive detection of genetic and molecular changes in cancer throughout a patient’s journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells. Epic Sciences has partnered with Genomic Health to commercialize the Oncotype DX AR-V7 Nucleus Detect test, which helps with therapeutic decisions between taxane chemotherapy or androgen-directed therapeutics in metastatic castrate-resistant prostate cancer.
Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available and offers best-in-class sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK.
Natera has developed Signatera, a personalized ctDNA test for molecular residual disease (MRD) detection and recurrence monitoring in patients previously diagnosed with cancer. Signatera's tumor-informed assay is optimized to detect low levels of ctDNA with high accuracy in identifying MRD and predicting recurrence with longer lead times. Signatera has been clinically validated in multiple cancer types. The test is available for clinical and research use, has been designated by the FDA as a Breakthrough Device, received CE mark. Look deeper at:
NeoGenomics is a premier cancer diagnostics and pharma services company serving oncologists, pathologists, pharmaceutical companies, academic centers, and others with innovative diagnostic, prognostic and predictive testing. Our vision embodies uncompromising quality, exceptional service, and innovative solutions. We have a network of CAP-accredited, CLIA-licensed facilities across the U.S., but work hard to maintain easy access and all the efficiencies of a smaller operation.
Almac Diagnostic Services is a stratified medicine company specialising in biomarker driven clinical trials. Our diagnostic experience spans oncology, immunology, CNS and infective diseases. Our global laboratories based in the UK and US, offer tailored solutions from discovery to commercialisation: Biomarker discovery. Custom assay development & validation. DNA and RNA panel solutions. Flexible CDx development & commercialisation. Expert regulatory support. Bioinformatics & software development. Your Clinical Trial Diagnostic Partner.
LabCorp brings together world-class diagnostics and drug development capabilities so patients have day one access to companion diagnostics and associated FDA approved therapies. Together, we are uniquely positioned at the intersection of research and patient care to enable more precise and individualized health care. Our menu of molecular, next generation sequencing and immuno-oncology assays are at the forefront of precision medicine, matching the right patient with the best treatment. We deliver Precision Medicine to patients through our commercially available and best in class genomic and immune-profiling tests.
At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.
Biodesix® is an experienced partner in the field of blood-based molecular diagnostic testing. Our comprehensive diagnostic testing capabilities help our partners decipher the complexity of cancer by interpreting genomic and proteomic information from both tumor biology and the patient’s immune response. Biodesix enables our partners throughout the discovery, development and commercialization of personalized diagnostics to support new therapies with companion diagnostic strategies.
ANGLE plc is a specialized medical diagnostics company with products in the cancer diagnostics and fetal health markets. ANGLE plc’s lead product, the Parsortix cell separation system, captures very rare cells from blood. This includes circulating tumor cells (CTCs) in cancer patient blood – even when there is less than one CTC per billion healthy cells. The resulting liquid biopsy allows investigation of mutations in the patient’s cancer, and enables precision medicine. ANGLE plc has launched a product for the research market and has secured CE Mark regulatory approval for the clinical market in Europe. The FDA approval process is underway for the clinical market in the US.
Claret Bioscience LLC, builds tools for improved precision oncology by developing novel next-generation sequencing (NGS) approaches for a deeper understanding of cell-free DNA fragmentomics . Their unique library preparation technologies SRSLY and XACTLY capture and encode native DNA termini information and other features of cfDNA fragmentation that are lost in traditional NGS methods. ClaretBio’s mission is to enhance the quality of DNA sequencing data obtained from highly degraded, low yield samples and provide tools for accurate disease profiling using DNA fragmentomics.
Since 2010 PlexBio has been designing, developing, and manufacturing our proprietary cutting-edge multiplexing platform and assays, to enable broad genetic research and more specifically, clinical cancer diagnostics. Our mission at PlexBio is to address the issue of rising healthcare costs and increasing number of available diagnostic tests, by creating simple, streamlines, and cost-effective laboratory solutions that will meet the demands of our growing world.
Burning Rock Dx specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology. With the unique capability and experience in global trials, we are looking for partnerships to advance the field of companion diagnostics in order to achieve better patient outcomes.